Sigmoid in licensing deal with Pendopharm for CyCol in Canada

29 September 2014

Privately-owned, Irish drug delivery technology company Sigmoid Pharma has entered into agreements with Canada’s Pendopharm, a division Pharmascience, concerning a licence for exclusive rights to commercialize CyCol in the Canadian market and an equity investment in Sigmoid. CyCol is Sigmoid’s proprietary oral formulation of solubilized cyclosporine targeted to the site of disease in the colon.

Under the licence deal, Sigmoid has received an upfront payment and will be eligible for future milestone payments in addition to significant double-digit, tiered royalties on net sales in Canada.

Deal includes 5 million-euro investment

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK